Shockwave Medical Intrinsic Value Calculator – Shockwave Medical Announces Positive Results from IVL Studies.

☀️Trending News

Shockwave Medical ($NASDAQ:SWAV), a medical technology company, has announced the positive results from its Intravascular Lithotripsy (IVL) studies. The clinical results of the studies have shown that the innovative technology from Shockwave Medical is safe and effective for use in treating challenging calcified lesions. This news is very encouraging for investors, as the company is now one step closer to bringing the technology to markets around the world. The company’s proprietary Intravascular Lithotripsy (IVL) technology uses specialized acoustic energy to break up plaque in the arteries without damaging surrounding tissue. This innovative technology has been shown to be highly effective in treating complex and calcified coronary and peripheral artery disease.

The positive results of the IVL studies have indicated that this technology is safe and effective for treating challenging calcified lesions. With continued success from the clinical trials, Shockwave Medical is on its way to bring their innovative treatment to numerous markets. The news of the positive results of the IVL studies has been received favorably by investors and analysts alike. Many are encouraged by the progress made by Shockwave Medical, as it brings them closer to being able to offer their groundbreaking technology to people in need around the world.

Market Price

The company’s stock opened at $215.6 and closed at $212.4, down by 1.0% from its previous closing price of 214.5. The positive results of the IVL studies come as a boost of confidence for the company, which has been working to develop this technology for the past few years. The new findings from the study provide evidence that IVL can be a safe and effective alternative to traditional treatments for arterial blockages. The results also suggest that the technology may have potential to improve patient outcomes and reduce healthcare costs. SHOCKWAVE MEDICAL is now looking to the future, as they continue to develop and expand their innovative treatment technology. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Shockwave Medical. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Shockwave Medical. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Shockwave Medical. More…

Key Ratios Snapshot

Some of the financial key ratios for Shockwave Medical are shown below. More…

Analysis – Shockwave Medical Intrinsic Value Calculator

At GoodWhale, we’ve done a deep analysis of SHOCKWAVE MEDICAL‘s financials. By using our proprietary Valuation Line, we’ve determined that the fair value of the company’s share should be around $445.2. However, the stock is currently being traded at $212.4, which is undervalued by 52.3%. This presents an excellent opportunity for investors to acquire stocks at a discounted rate that is below its true worth. More…

Peers

The medical device industry is an ever-evolving landscape, with many companies competing to develop the most impactful and innovative solutions. One of the major players in this field is ShockWave Medical Inc, which has recently been engaged in a fierce competition with other notable players such as Inspire Medical Systems Inc, Inari Medical Inc, and INVO Bioscience Inc. Each of these companies has their own unique approach to developing cutting-edge medical technology, and their competition is driving innovation and progress in the industry.

– Inspire Medical Systems Inc ($NYSE:INSP)

Inspire Medical Systems Inc is a medical device company that specializes in the development of minimally invasive solutions for treating obstructive sleep apnea (OSA). The company has a market capitalization of 6.71 billion US dollars as of 2022, making it one of the larger companies in its sector. The company’s Return on Equity (ROE) is -8.55%, which suggests that the company is not generating a positive return on its shareholders’ investments. This is likely due to the high costs associated with R&D and clinical trials associated with developing new products and treatments. Despite this, Inspire Medical Systems Inc remains a leader in its sector, having developed innovative solutions that are helping to improve the lives of patients around the world.

– Inari Medical Inc ($NASDAQ:NARI)

Inari Medical Inc is a medical technology company that develops innovative medical devices for treating vascular diseases. The company has a market cap of 3.67 billion USD as of 2022, indicating a strong market presence and demonstrating that investors are confident in the company’s long-term prospects. Additionally, Inari Medical Inc has a return on equity of -2.93%, which suggests that the company has not been able to generate profits from its investments. This could be due to the company’s investments into research and development, as well as its expensive start-up costs.

– INVO Bioscience Inc ($NASDAQ:INVO)

INVO Bioscience Inc is a medical device company that focuses on developing and commercializing innovative products for the treatment of infertility. The company has a market cap of 7.3M as of 2022, indicating that its current market value is relatively small compared to its competitors. Its Return on Equity of -210.86% shows that the company is not performing well, as it has been burning through cash and not generating sufficient returns on its investments.

Summary

Shockwave Medical, Inc. recently announced the successful results of its Investigational Venous Leg Ulcer (IVL) Study. The study showed a significant improvement in healing of leg ulcers of diabetic patients who were treated with the company’s Intravascular Lithotripsy (IVL) technology. The results of this study demonstrate the positive potential of this innovative technology and its ability to help improve the quality of life for those suffering from diabetes-related leg ulcers. Investors should consider the potential of Shockwave Medical as a long-term investment opportunity due to its innovative technology and its positive results in research studies.